Efficacy of emapalumab in the management of anti‑CD19 chimeric antigen receptor T‑cell therapy‑associated cytokine release syndrome: A report of two cases

Chimeric antigen receptor (CAR) T-cell therapy is an effective treatment for diffuse large B-cell lymphoma (DLBCL). However, it may activate the systemic immune system of the patient, resulting in cytokine release syndrome (CRS). Emapalumab is a human monoclonal antibody targeting interferon-γ, inhi...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2025-02, Vol.29 (2), Article 71
Main Authors: Cai, Wenzhi, Lu, Yutong, He, Haiju, Li, Jiaqi, Liu, Shuangzhu, Geng, Hongzhi, Yang, Qin, Zeng, Liangyu, Wu, Depei, Li, Caixia
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Blood pressure
Case Report
Cells
Chemotherapy
Cytokine storm
Data analysis
Fever
Genetic testing
Hematology
Hypotension
Lymphocytes
Lymphoma
Medical prognosis
Metabolism
Monoclonal antibodies
Patients
Proteins
Steroids
Survival analysis
Testing laboratories
Transplants & implants
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chimeric antigen receptor (CAR) T-cell therapy is an effective treatment for diffuse large B-cell lymphoma (DLBCL). However, it may activate the systemic immune system of the patient, resulting in cytokine release syndrome (CRS). Emapalumab is a human monoclonal antibody targeting interferon-γ, inhibiting its interaction with cell surface receptors and the subsequent activation of inflammatory pathways. The present report describes the cases of 2 patients with relapsed DLBCL treated with CAR T-cell therapy, in which the severe CRS associated with CAR T-cell therapy was attenuated without compromising antitumor efficacy after receiving emapalumab. Further prospective clinical trials are warranted to determine the role of emapalumab in CAR T-cell therapy.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2024.14817